Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
32 results about "Antiangiogenesis Therapy" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A therapeutic regimen that uses synthetic compounds or natural substances to prevent the development of new blood vessels.
Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
InactiveUS20060134111A1Reduce riskAntipyreticAnalgesicsAngiogenesis AntagonistsAntiangiogenesis Therapy
The present application describes therapy with angiogenesis antagonists such as anti-VEGF antibodies. In particular, the application describes the use of such antagonists to treat autoimmune disease in a patient who has failed prior treatment such as treatment with DMARDs or TNFα-inhibitors.
Owner:GENENTECH INC
Detection of activation of endothelial cells as surrogate marker for angiogenesis
InactiveUS20060199231A1Sensitively and conveniently measurePeptide preparation methodsDepsipeptidesCellular componentProtein-protein complex
Methods, compositions and kits are provided for assessing angiogenesis through sensitive, direct detection of activation of endothelial cells at molecular levels. In general, activation of endothelial cells is detected by measuring the levels of cellular components and their protein complexes participating in a specific angiogenesis signaling pathway in endothelial cells. The methods can be used for assessing status of diseases associated with undesirable angiogenesis, such as the likelihood of developing the disease, presence or absence of the disease, prognosis of the disease and the likelihood of response or resistance to a particular anti-angiogenic therapy. The methods can also be used to guide the design of effective therapeutic regimens targeting a specific angiogenic signaling pathway, as well as in conjunction with therapeutic intervention of diseases or conditions associated with undesirable angiogenesis.
Owner:MONOGRAM BIOSCIENCES
Use of anti-α5β1 antibodies to inhibit cancer cell proliferation
InactiveUS7662384B2Prevent proliferationPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntiangiogenesis TherapyAntiendomysial antibodies
The present invention provides methods for direct killing of cancer cells using anti-α5β1 antibodies. Generally, the method comprises contacting a cancer cell that expresses α5β1 on its surface with an anti-α5β1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at an early stage of cancer development in a patient to prevent tumor establishment. In addition, the methods may be used to treat previously formed tumors especially in cancer that have not proven susceptible to anti-angiogenesis therapy. The methods may be employed as a combination therapy of anti-α5β1 antibodies together with cancer chemotherapeutic agents or other molecular-based cancer therapeutic agents.
Owner:ABBOTT BIOTHERAPEUTICS CORP
Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
InactiveUS20050260210A1Prevent proliferationPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAbnormal tissue growthAntiangiogenesis Therapy
The present invention provides methods for direct killing of cancer cells using anti-α5β1 antibodies. Generally, the method comprises contacting a cancer cell that expresses α5β1 on its surface with an anti-α5β1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at an early stage of cancer development in a patient to prevent tumor establishment. In addition, the methods may be used to treat previously formed tumors especially in cancer that have not proven susceptible to anti-angiogenesis therapy. The methods may be employed as a combination therapy of anti-α5β1 antibodies together with cancer chemotherapeutic agents or other molecular-based cancer therapeutic agents.
Owner:ABBOTT BIOTHERAPEUTICS CORP
Using cardiac troponin for monitoring Anti-angiogenesis therapy
The present invention relates to a method for monitoring subjects being on anti-angiogenesis therapy based on determining the amount of a cardiac troponin in a first and second sample of a subject and comparing the amount in the first sample with the second sample. Thereby, it can be assessed whether a subject is susceptible to a continuation of the therapy or not. Moreover, the present invention relates to a method for predicting the risk of a cardiovascular event as a consequence of anti-angiogenesis therapy. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.
Owner:ROCHE DIAGNOSTICS OPERATIONS INC
Combined administration of integrin receptor antagonists for Anti-angiogenic therapy
InactiveUS20110319335A1Peptide/protein ingredientsAntineoplastic agentsAntiangiogenesis TherapyMedicine
The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an αvβ3 antagonist with an α2β1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of echistatin and VP12 (ECL12).
Owner:CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY
Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
InactiveUS20170253933A1Organic active ingredientsHeavy metal active ingredientsAntiangiogenesis TherapySelection criterion
The invention provides methods of using expression levels of one or more stroma signature genes as selection criteria for determining a patient with cancer that is chemotherapy-resistant who may benefit from a particular anti-cancer therapy, such as stroma-targeted therapy, anti-angiogenic therapy, and / or immunotherapy. The present invention also provides methods of using expression levels of one or more stroma signature genes as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a stroma-targeted agent.
Owner:GENENTECH INC
VEGF polymorphisms and Anti-angiogenesis therapy
ActiveUS20110176993A1Raise the possibilityIncreased riskIn-vivo radioactive preparationsMicrobiological testing/measurementAntiangiogenesis TherapyHypertension risk
Owner:GENENTECH INC
Vaccine based on simulating human blood vessel endothelial cell growth factor VEGF epitope and preparation method thereof
InactiveCN101429234APrevent proliferationInhibit migrationLibrary screeningPeptidesAntiangiogenesis TherapyVascular endothelium
The invention provides a vaccine based on an epitope simulating human vascular endothelial growth factor VEGF, as well as a preparation method thereof. A VEGF mimic epitope which is specifically affinitive with human-mouse chimeric monoclonal antibody Avastin is screened out by use of a phage random presentation technique, and the amino acid sequence of the mimic epitope is Asp-His-Thr-Leu-Tyr-Thr-Pro-Tyr-His-Thr-His-Pro; the mimic epitope has no homology with the protein sequence of VEGF. A vaccine which can induce a polypeptide epitope aiming at VEGF molecular autoantibody in vivo is constructed on the basis of the mimic epitope. The invention provides a strategy for developing and designing the tumor therapeutic vaccine, which is targeted at the VEGF. The VEGF is one of molecules which has the strongest effect of promoting vascular growth, and is an ideal target for resisting angiogenesis and treating tumors. Therefore, the vaccine replaces or replenishes monoclonal antibody passive immunotherapy with an active immunity mode, so as to lay foundations for overcoming the defects of monoclonal antibody therapy.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
Disclosed are copper-binding compounds with improved properties and methods of using such compounds in the prevention and treatment of angiogenic diseases, such as cancer. Advantages of the invention include the enhanced stability of the compounds, which is achieved without reduction in efficacy. Pharmaceutical compositions, therapeutic kits and combination treatment methods and uses are also provided.
Owner:RGT UNIV OF MICHIGAN
Compounds useful for treating ocular neovasculan
ActiveUS20150274668A1Normalising brain neural networksNormalising the sensitivity towards painBiocideSenses disorderAntiangiogenesis TherapyEclampsia
Anti-angiogenic treatments, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of reducing the risk of pre-eclampsia and compounds for use in such methods are described.
Owner:EXONATE
Bio-click-triggered high-efficiency targeting conjugate and bio-click-triggered high-efficiency targeting multi-component composition as well as preparation methods and application thereof
ActiveCN109675052ASuppress generationPrevent recurrenceOrganic active ingredientsEnergy modified materialsAntiangiogenesis TherapySide effect
The invention discloses a bio-click-triggered high-efficiency targeting conjugate and a bio-click-triggered high-efficiency targeting multi-component composition as well as preparation methods and application thereof. The multi-component composition is formed by assembling an anti-angiogenic therapeutic agent, a chemotherapeutic drug and a photosensitizer in the same nano-system; furthermore, thetargeting conjugate (a cycloalkyne-heparin polysaccharide-natural active hydrophobic medicine) is modified with a small molecular target with a cycloalkyne structure, so that in-vivo click targeting is efficiently realized. After nanoparticles are formed in water by means of self-assembly, a chemotherapeutic medicine and a thermotherapy photosensitizer are simultaneously encapsulated in hydrophobic cores of the nanoparticles by using a physical method; therefore, the toxic and side effects on the normal tissues are greatly reduced while the combined administration is realized; the conjugate and the multi-component composition have the characteristics of being intelligent, efficient and low in toxicity, having targeting property, reversing tumor MDR, having a synergistic anti-tumor effect,and the like; a brand-new combined chemotherapy model is created.
Owner:CHINA PHARM UNIV
Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer
InactiveUS10280468B2Microbiological testing/measurementAntineoplastic agentsAntiangiogenesis TherapyAnti-angiogenic drugs
Owner:ALMAC DIAGNOSTICS SERVICES LIMITED
Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses
ActiveUS10837966B2Improve responsivenessGood curative effectSerum immunoglobulinsImmunoglobulins against growth factorsAntiangiogenesis TherapyAntiendomysial antibodies
Owner:DANA FARBER CANCER INST INC
Biomaterials based on hyaluronic acid for the anti-angiogenic therapy in the treatment of tumors
ActiveUS20050037049A1BiocidePeptide/protein ingredientsAbnormal tissue growthAntiangiogenesis Therapy
The use in the medical-surgical field of biomaterials based on hyaluronic acid derivatives, optionally in association with natural, synthetic or semisynthetic biopolymers, for suppressing the angiogenic process associated with tumour proliferation (in primary and secondary tumours) is disclosed.
Owner:FIDIA FARM SPA +1
Medicine composition for inhibiting pancreatic cancer and application of medicine composition
InactiveCN105343048AAnti-tumor effectImproving the effectiveness of pancreatic cancer treatmentPeptide/protein ingredientsAntibody ingredientsAntiangiogenesis TherapyBevacizumab Injection
The invention discloses a medicine composition for inhibiting pancreatic cancer. The medicine composition comprises cantharidin and cantharidin derivatives, as well as a medicine withan anti-angiogenic effect, wherein antharidin and the cantharidin derivatives are selected from one or more of cantharidin, norcantharidin and disodium cantharidinate; the medicine with the anti-angiogenic effect is selected from one or more of bevacizumab, endostar and apatinib. Experiments prove that cantharidin and bevacizumab have a synergistic effect to improve the pancreatic cancer treatment effect of the medicine composition; under the premise that the anti-angiogenic medicine is used for treatment, the anti-tumor effect of cantharidin is obvious. A formula comprising bevacizumab and cantharidin has a clinical application prospect.
Owner:THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV
Compounds useful for treating ocular neovasculan
ActiveUS10301264B2Normalising brain neural networksNormalising the sensitivity towards painSenses disorderNervous disorderAntiangiogenesis TherapyEclampsia
Owner:EXONATE
Inhibition of ferrochelatase as an antiangiogenic therapy
ActiveUS10752901B2Organic active ingredientsPharmaceutical delivery mechanismAntiangiogenesis TherapyDisease
Owner:INDIANA UNIV RES & TECH CORP
Piperazine derivatives for treating disorders
ActiveUS9695160B2Reduce riskAvoid painOrganic active ingredientsSenses disorderAntiangiogenesis TherapyEclampsia
Anti-angiogenic treatments, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of reducing the risk of pre-eclampsia and compounds for use in such methods are described.
Owner:EXONATE
VEGF polymorphisms and anti-angiogenesis therapy
ActiveUS10031141B2Microbiological testing/measurementDisease diagnosisAntiangiogenesis TherapyHypertension risk
Owner:GENENTECH INC
Detection of Activation of Endothelial Cells as Surrogate Marker for Angiogenesis
InactiveUS20110275096A1Sensitively and conveniently measureDisease diagnosisBiological testingAntiangiogenesis TherapyCellular component
Methods, compositions and kits are provided for assessing angiogenesis through sensitive, direct detection of activation of endothelial cells at molecular levels. In general, activation of endothelial cells is detected by measuring the levels of cellular components and their protein complexes participating in a specific angiogenesis signaling pathway in endothelial cells. The methods can be used for assessing status of diseases associated with undesirable angiogenesis, such as the likelihood of developing the disease, presence or absence of the disease, prognosis of the disease and the likelihood of response or resistance to a particular anti-angiogenic therapy. The methods can also be used to guide the design of effective therapeutic regimens targeting a specific angiogenic signaling pathway, as well as in conjunction with therapeutic intervention of diseases or conditions associated with undesirable angiogenesis.
Owner:MONOGRAM BIOSCIENCES
Methods and compositions for targeting vascular mimicry
InactiveUS20190105340A1Assess efficacyOrganic active ingredientsImmunoglobulins against growth factorsAntiangiogenesis TherapyFOXC2
A method for increasing the sensitivity of a tumor to anti-angiogenic therapy comprises treating a patient having a tumor with an anti-angiogenic therapeutic composition or compound and substantially simultaneously inhibiting vascular, or vasculogenic, mimicry (VM). In one embodiment, such a method includes the inhibition of VM by administering a therapeutic compound that inhibits the activity or pathway of the transcription factor FOXC2. In another embodiment, such a method includes administering a therapeutic compound that activates or enhances the activity or pathway of IRE1 and / or inhibits its target genes. In another embodiment, all three compositions are administered to the subject either simultaneously or sequentially.
Owner:NEW YORK GENOME CENT
Application of CD93 in preparation of early warning infantile hemangioma (IH) umbilical blood assay kit and therapeutic drug
InactiveCN110389165AEasy to acceptReduce the rate of teratogenicityPeptide/protein ingredientsMicrobiological testing/measurementAntiangiogenesis TherapyTransmembrane protein
Owner:江成鸿
A recombinant human endostatin imaging agent and its preparation method
InactiveCN103861129BDifference in biological activityRadioactive preparation carriersAntiangiogenesis TherapyImaging agent
The invention relates to the technical field of recombinant human endostatin preparation prepared molecular targeting developers, and concretely provides a novel positron-emitting radionuclide or gadolinium labeled recombinant human endostatin developer and its application in the evaluation and the predication of the curative effective of the antiangiogenetic therapy through the noninvasive and dynamic observation of the conditions of new vessels of a plurality of tumors. The invention also provides a preparation method of the developer. The positron-emitting radionuclide or gadolinium can be combined with human endostatin through a bifunctional chelating agent.
Owner:SHANDONG RES INST OF TUMOUR PREVENTION TREATMENT +1
Compounds
ActiveUS20190062317A1Normalising brain neural networksNormalising the sensitivity towards painOrganic active ingredientsSenses disorderDiseaseAntiangiogenesis Therapy
Anti-angiogenic treatments, for example treatment of ocular neovascularization or cancer, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of treating or preventing fibrosis and compounds for use in such methods are described.
Owner:EXONATE
Anti-angiogenic therapy based on exosomes derived from menstrual stem cells
ActiveUS11040071B2Lower Level RequirementsDecrease angiogenic capacity of tumorsOrganic active ingredientsMammal material medical ingredientsAntiangiogenesis TherapyPancreas Cancers
The present invention offers a solution to the lack of an effective alternative method to those already known to treat angiogenesis. In particular, the present invention is the first to show that a substantially pure population of exosomes derived from MenSCs have capacity to reduce tumor angiogenesis in diseases such as prostate cancer, breast cancer and pancreatic cancer. In this sense, the present invention shows that a substantially pure population of MenSCs-derived exosomes reduce the endogenous levels of reactive oxygen species (ROS) in cancer cells and the expression of pro-angiogenic factors such as VEGF, NF-KB, FGF and HIFα in the treated tumors. Overall, the invention offers a promising alternative method to treat angiogenesis. Since it is principally composed of exosomes produced by the Stem cells present in menstrual fluid, the invention provides an ease access and repeated sampling in a non-invasive manner. Such attributes allow the rapid production of the treatment.
Owner:CELLS FOR CELLS
Vaccine based on simulating human blood vessel endothelial cell growth factor VEGF epitope and preparation method thereof
InactiveCN101429234BPrevent proliferationInhibit migrationLibrary screeningPeptidesAntiangiogenesis TherapyVascular endothelium
The invention provides a vaccine based on an epitope simulating human vascular endothelial growth factor VEGF, as well as a preparation method thereof. A VEGF mimic epitope which is specifically affinitive with human-mouse chimeric monoclonal antibody Avastin is screened out by use of a phage random presentation technique, and the amino acid sequence of the mimic epitope is Asp-His-Thr-Leu-Tyr-Thr-Pro-Tyr-His-Thr-His-Pro; the mimic epitope has no homology with the protein sequence of VEGF. A vaccine which can induce a polypeptide epitope aiming at VEGF molecular autoantibody in vivo is constructed on the basis of the mimic epitope. The invention provides a strategy for developing and designing the tumor therapeutic vaccine, which is targeted at the VEGF. The VEGF is one of molecules whichhas the strongest effect of promoting vascular growth, and is an ideal target for resisting angiogenesis and treating tumors. Therefore, the vaccine replaces or replenishes monoclonal antibody passive immunotherapy with an active immunity mode, so as to lay foundations for overcoming the defects of monoclonal antibody therapy.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
A peptide-modified stealth nanoparticle loaded with anti-tumor angiogenesis drug and its application
InactiveCN101822642BIncrease concentrationReduce concentrationPowder deliveryOrganic active ingredientsAntiangiogenesis TherapySide effect
The invention relates to a K237 peptide modified invisible nano particle loaded with an anti-tumor angiogenesis drug. The invisible nano particle consists of the anti-tumor angiogenesis drug, K237 peptide and an invisible nano particle. The invention further provides a preparation method and application of the K237 peptide modified invisible nano particle loaded with the anti-tumor angiogenesis drug. The invention selectively targets the newly generated tumor blood vessels, greatly improves the concentration of the anti-tumor angiogenesis drug (such as the concentration of paclitaxel) in the chrotoplast in the blood vessels, maximumly reduces the concentration of the anti-tumor angiogenesis drug in the normal organs, and overcomes the side-effects caused by the distribution of the drug throughout the body. Since the therapeutic target is the chrotoplast in the tumor blood vessels, drug resistance can not be developed, and the nano particle is potentially effective to the tumor which is already in existence and is resistant to multiple anti-tumor angiogenesis drugs (such as paclitaxel). The invention aims to realize anti-angiogenic tumor therapy and the invisible nano particle can also restrain the metastasis and recrudescence of tumors.
Owner:SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
The present application describes therapy with angiogenesis antagonists such as anti-VEGF antibodies. In particular, the application describes the use of such antagonists to treat autoimmune disease in a patient who has failed prior treatment such as treatment with DMARDs or TNFα-inhibitors.
Owner:GENENTECH INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com